# **PCRS-UK Protocols**

# COPD assessment and review in primary care



This protocol has been developed specifically to be utilised by primary care nurses delivering respiratory care. It has also been produced in Microsoft WordTM format as a general guide only, to allow for local adaptation. It must be stressed that the use of all, or part, of this protocol must be sanctioned and approved by the appropriate authorised individual from the practice or primary care organisation in which it is to be used.

The PCRS-UK is neither responsible or liable, directly or indirectly for any form of damage or injury caused as a result of information provided in this document.

#### Introduction

Chronic obstructive pulmonary disease (COPD) is characterised by airflow obstruction, which is defined by spirometry as a reduced FEV<sub>1</sub>/FVC ratio less than 0.7. FEV<sub>1</sub> helps us to look at the severity of the problem. If FEV<sub>1</sub> is  $\geq$  80% predicted a diagnosis of COPD can be made in the presence of respiratory symptoms, for example breathlessness or cough but there still needs to be obstruction so a rexduced FEV<sub>1</sub>/FVC ratio < 0.7 The airflow obstruction is usually progressive, not fully reversible and does not change markedly over several months. The disease is predominantly caused by smoking.<sup>1</sup>

# Presentation

A diagnosis of COPD should be considered in the following patients:

Patients over 35 with a significant smoking history (15 pack years or more) who have one or more of the following respiratory symptoms:

- Chronic cough which is present intermittently or every day
- Chronic sputum production
- Dyspnoea which is progressive, persistent, worse on exercise, worse during respiratory infections
- History of exposure to risk factors i.e. smoking, occupational dusts and chemicals
- No clinical features of asthma

Clinical signs of COPD do not tend to be apparent until disease becomes severe:

- Barrel chest
- Prominent accessory muscles
- Abdominal breathing
- Weight loss
- Central cyanosis
- Peripheral oedema
- Raised jugular venous pressure
- Chest overinflation

After initial assessment (see figure 1) a review date should be agreed. If new therapies have been started, offer review 1-2 months after changing treatment. If lifestyle changes are being made review according to goals set with the patient. Patient review should also be offered after an exacerbation or hospital admission. Routine reviews should be offered annually to patients with mild to moderate COPD. In patients

with more severe disease follow up should be offered at least every six months.

#### **Assessment**


- Breathlessness and exercise tolerance (use MRC dyspnoea score<sup>2</sup>, see page 2)
- Frequency of exacerbations
- Presence of complications
- Effects of drug treatment, discontinue treatments with no subjective benefit (use Jones 5 questions<sup>3</sup> to assess effectiveness)
- Inhaler technique and provide education where appropriate
- Smoking status and desire to guit

#### **Action**

- Give smoking cessation advice or health education where appropriate
- Review need to refer for pulmonary rehabilitation
- Check for the presence of cor pulmonale
- Review need for osteoporosis prevention
- Review nutritional status
- Screen for depression (use NICE¹ guidance questions, see page 2)
- Assess requirement for social services or occupational therapy input
- Consider other co-morbidities as a cause for symptoms

# Criteria for referral to Chest Physician

- Diagnostic doubt
- Specialist investigations or treatment
- Very severe disease
- Long term nebuliser therapy or oral steroid therapy
- Frequent infections, dysfunctional breathing or haemoptysis
- Patients under 40 or family history of α1 antitrypsin deficiency
- Rapid decline in FEV<sub>1</sub> or increase in symptoms disproportionate to lung deficit
- Assessment for lung volume reduction therapy or lung transplantation
- Long Term Oxygen Therapy (LTOT)
- The need for LTOT should be assessed in patients with:
  - MRC score<sup>2</sup> = 3 or more
  - Severe airflow obstruction (FEV<sub>1</sub><30% predicted)</li>
  - Cyanosis or peripheral oedema or polycythaemia



- Raised jugular venous pressure
- Oxygen saturations <92% breathing air</li>

## **Measurements**

- Spirometry
- BMI
- Pulse oximetry (SaO<sub>2</sub>)

# **Useful Tools**

#### Jones 5 questions<sup>3</sup>

- 1. Has your treatment made any difference to you?
- 2. Is your breathing easier in any way?
- 3. Can you do some things now that you couldn't do before or the same things faster?
- 4. Can you do the same things as before but are now less breathless when you do them?
- 5. Has your sleep improved?

# MRC dyspnoea score<sup>2</sup>

- Not troubled by breathlessness except on strenuous exercise
- 2. Short of breath when hurrying or walking up a slight hill
- 3. Walks slower than contemporaries on level ground

- because of breathlessness or has to stop for breath when walking at own pace
- 4. Stops for breath after walking about 100 metres or after a few minutes on level ground
- Too breathless to leave the house or breathless when getting undressed

# CAT (COPD assessment tool)5

The CAT is a short, simple and validated assessment, which measures the impact of COPD on a patient's life in an objective manner. It helps discussion between people with COPD and health care professionals of the impact of the disease allowing management to be tailored to the individual person with COPD.

## NICE Guidance on Depression

- 1. During the last month have you been bothered by feeling down, depressed or hopeless?
- 2. During the last month have you often been bothered by having little interest or pleasure in doing things?

A positive test is the answer of "yes" to either of the questions above; refer to GP for further investigation.

#### Algorithm - Clinical features differentiating COPD and asthma COPD Asthma Nearly all Possibly Smoker or ex-smoker Symptoms under age 35 Rare Common Chronic productive cough Common Uncommon Breathlessness Variable Persistent & progressive Night-time waking with breathlessness and / or wheeze Uncommon Common Significant diurnal or day-to-day variability of symptoms Uncommon Common

	Initial C	COPD As:	sessment Form				
(Please	note relevant read code	es in brackets	for nGMS contract, complete COF	PD template)			
Patient name Date// Heightcm	Weightk		Date last measured Type (cylinder/concentrator)? Hours per day	// Flow rate (L/min)			
BMI DOB / / Ethnicity	□ male □ female Age	_	Nebuliser therapy Compressor maintained? Oral steroids	ges no			
Present			Osteoporosis prevention	□ yes □ no □ yes □ no			
History of breathing problems:  □ Childhood onset  □ Occupational Comment	□ Family history □ Other		Under the care of:  Last seen:  Further investigations				
Existing respiratory diagnosis  COPD  Asthma	□ COPD/asthma □ Other	_	To exclude underlying causes of breathlessness, such as lung cancer, anaemia, cardiac causes, sleep apnoea, bronchiectasis, consider the following:  Chest X-ray				
Concomitant disease		_	<ul><li>ECG/Echocardiogram</li><li>Full Blood count</li><li>Sleep studies</li><li>CT scan</li></ul>				
Consolida su estatura :			Exercise tolerance				
Smoking status:  Yes (137R)  Ex-smoker (137S)  Pack years  (no cigs smoked/20 x no years sm	□ Never (1371) □ Passive (137I) oked)		MRC dyspnoea score (1-5) Impact of activities:				
Symptoms Breathlessness:			Current Management				
□ Variable □ sudden attacks  Onset: □ Recent □ over many years  Trigger factors	□ most days		Drug: Dose: Delivery device: Prescribed regime: Patient actual use:				
Cough Productive Sputum type?	g yes g no		Spacer device  Comment	□ yes □ no			
Haemoptysis Haemoptysis can be a symptom or	□ yes □ no f lung cancer: a CXR is i	mandatory	Refer to NICE COPD guideline management options	es (2010) for			
Result			Education given				
Oxygen therapy Blood Gases O <sub>2</sub>	□ yes □ no CO <sub>2</sub>		Comment:	<del></del>			

Exacerbation management/self	Exacerbation management/self								
Exacerbation management/self	Domment:	□ Exercise				□ Pneumoco	ccal vaccinati	on	
Lifestyle omment:  Inhaler technique omment:  Smoking cessation (8CAL)  omment:  Smoking cessation (8CAL)  omment:  Good (663H)   bad (663I)   shown (6636)  ducation given continued  Influenza vaccination advice 65E flu vac given  Pre-actual   % predicted   Post actual   % predi	Lifestyle omment:    Inhaler technique omment:   Smoking cessation (8CAL)   Referrals made to   Pulmonary rehab   Smoking cessation service   Consultant/Chest physician   Other e.g. COPD Nurse Specialist other AHP   Dietician   Psychologist   Breathe Easy Group      Influenza vaccination advice   Psychologist   Breathe Easy Group				Exacerbation management/self management				
Inhaler technique omment:  Smoking cessation (8CAL) omment:  Smoking cessation (8CAL)  Omment:  Smoking cessation (8CAL)  Smoking cessation service  Consultant/Chest physician  Consultant/Chest physician  Other e.g. COPD Nurse Special other AHP  ducation given continued  Influenza vaccination advice  65E flu vac given  Pre-actual % predicted Post actual % predicted  FEV1/FVC ratio (339R)  FVC (3396)  VC  Unique function assessment indicates:  Normal lung function  Referrals made to  Pulmonary rehab  Consultant/Chest physician  Other e.g. COPD Nurse Special other AHP  Dietician  Psychologist  Breathe Easy Group  NIF  reconsincreates  FEV1/FVC ratio (339R)  FVC (3396)  VC  Unique function assessment indicates:  Normal lung function  Moderate COPD (% predicted FEV1)  Severe COPD (% predicted FEV1)	Inhaler technique omment: Smoking cessation (8CAL) omment: Smoking cessation (8CAL) omment: Smoking cessation service Smoking cessation service Consultant/Chest physician Consultant/	□ Lifestyle				Comments	· ·		
Smoking cessation (8CAL)  omment:  Smoking cessation (8CAL)  omment:  Chaler technique  Good (663H)  Cher e.g. COPD Nurse Special other AHP  ducation given continued  Influenza vaccination advice  65E flu vac given  Pre-actual  Pre	Smoking cessation (8CAL)  omment:  Smoking cessation (8CAL)  omment:    Pulmonary rehab     Smoking cessation service     Consultant/Chest physician     Other e.g. COPD Nurse Specialist other AHP     Dietician     Influenza vaccination advice     65E flu vac given     Pre-actual   % predicted     Post actual   % predicted     FEV₁/FVC ratio     (339R)     FEV₁     (3390)     (339S)     FVC     (3396)     VC     Ung function assessment indicates:  Normal lung function     Referrals made to     Pulmonary rehab     Smoking cessation service     Consultant/Chest physician     Other e.g. COPD Nurse Specialist other AHP     Dietician     Psychologist     Breathe Easy Group     NICE recommendation     FEV₁/FVC ratio     (339R)     FEV₁     significant     (post FEV₁     significant     (post FEV₁     Severe COPD (% predicted FEV₁     Wery severe (% predicted < 30%)	Comment:							
Smoking cessation (8CAL)  omment:    Pulmonary rehab     Smoking cessation service     Consultant/Chest physician     Other e.g. COPD Nurse Special other AHP     Dietician     Influenza vaccination advice     65E flu vac given     Pre-actual   Pre-actual     Pre-actual   Pre-actual     FEV1/FVC ratio     F2V1     FVC     (3390)     FVC     (3396)     VC     Understand the comment of the commen	Smoking cessation (8CAL) Referrals made to   omment: □ Pulmonary rehab   □ Smoking cessation service □ Consultant/Chest physician   Good (663H) □ bad (663l) □ shown (6636)   □ Other e.g. COPD Nurse Specialist other AHP   ducation given continued □ Dietician   Influenza vaccination advice □ Psychologist   65E flu vac given □ Breathe Easy Group    Pre-actual  Post actual  Pre-actual  Pre-actual  Pre-actual  Pre-actual  Post actual  Pre-actual  Pre-actual  Pre-actual  Pre-actual  Pre-actual  Pre-actual  Post actual  Pre-actual  Pre-actual  Pre-actual  Pre-actual  Pre-actual  Pre-actual  Pre-actual  Post actual  Pre-actual	□ Inhaler technique							
Pulmonary rehab   Smoking cessation service   Consultant/Chest physician   Other e.g. COPD Nurse Special other AHP   Dietician   Dietician   Psychologist   Breathe Easy Group	Pulmonary rehab   Smoking cessation service   Consultant/Chest physician   Other e.g. COPD Nurse Specialist other AHP   Dietician   Psychologist   Breathe Easy Group								
Smoking cessation service   Consultant/Chest physician   Other e.g. COPD Nurse Special other AHP   Dietician   Psychologist   Breathe Easy Group	Smoking cessation service   Consultant/Chest physician   Consultant/Chest physician   Other e.g. COPD Nurse Specialist other AHP   Dietician   Psychologist   Breathe Easy Group								
Consultant/Chest physician	Consultant/Chest physician   Consultant/Chest physician   Other e.g. COPD Nurse Specialist other AHP   Dietician   Psychologist   Breathe Easy Group	comment:				•		20	
Good (663H)   bad (663I)   shown (6636)   Other e.g. COPD Nurse Special other AHP   ducation given continued   Dietician   Influenza vaccination advice   Psychologist   65E flu vac given   Breathe Easy Group      Pre-actual   % predicted   Post actual   % predicted     FEV1/FVC ratio   (339R)   FVC   (3396)     VC   (3396)   VC   (905 FEV     Lung function assessment indicates:   Normal lung function     Restriction   Moderate COPD (% predicted FEV     Severe COPD (% predicted FEV     Se	Good (663H) □ bad (663I) □ shown (6636) □ Other e.g. COPD Nurse Specialist other AHP  ducation given continued  Influenza vaccination advice 65E flu vac given □ Psychologist □ Breathe Easy Group  pirometry results (pre and post reversibility) and oxygen saturation    Pre-actual   % predicted   Post actual   % predicted	nhaler technique				-			
ducation given continued  Influenza vaccination advice 65E flu vac given  Pre-actual % predicted Post actual % predicted  FEV1/FVC ratio (339R)  FVC (3396)  VC  Pre-actual (3396)  FVC	other AHP Dietician Influenza vaccination advice 65E flu vac given  Pre-actual FEV₁/FVC ratio FEV₁/FVC ratio FVC	•	oad (663I) □ sh	own (6636)					
Influenza vaccination advice 65E flu vac given  Pre-actual % predicted Post actual % predicted  FEV1/FVC ratio (339R)  FVC (3396)  VC (3396)  In signification with the product of the pro	Influenza vaccination advice 65E flu vac given    Pre-actual   % predicted   Post actual   % predicted	, ,	,	,		•			
pirometry results (pre and post reversibility) and oxygen saturation  Pre-actual % predicted Post actual % predicted  FEV1/FVC ratio (339R)  FVC (3396)  VC (3396)  Understand the Easy Group  Nitrocconsincreal FEV1 significates:  Normal lung function assessment indicates:  Normal lung function  Restriction Moderate COPD (% predicted FEV1 Severe COPD)	pirometry results (pre and post reversibility) and oxygen saturation  Pre-actual % predicted Post actual % predicted FEV₁/FVC ratio (339R) FVC (3396) VC (3396) VC (3396) VC (300   Moderate COPD (% predicted FEV₁ Associated FEV₁ Associate	•				□ Dietician			
pirometry results (pre and post reversibility) and oxygen saturation    Pre-actual	pirometry results (pre and post reversibility) and oxygen saturation    Pre-actual		on advice			, ,			
Pre-actual % predicted Post actual % predicted  FEV <sub>1</sub> /FVC ratio (339R)  FEV <sub>1</sub> (3390) (339S)  FVC (3396)  VC  Lung function assessment indicates:  Normal lung function  Restriction  Moderate COPD (% predicted FEV <sub>1</sub> Severe COPD (% predicted FEV <sub>1</sub> Sever		□ 65E flu vac given				□ Breathe Ea	sy Group		
FEV <sub>1</sub> /FVC ratio (339R)  FEV <sub>1</sub> (3390) (339S)  FVC (3396)  VC  Lung function assessment indicates:  Normal lung function  Restriction  Moderate COPD (% predicted FEV <sub>1</sub> Severe COPD (% predic	FEV <sub>1</sub> /FVC ratio (339R)  FEV <sub>1</sub> (3390) (339S)  FVC (3396)  VC  ung function assessment indicates:  Normal lung function  Restriction  Mild COPD (% predicted FEV <sub>1</sub> $\geq$ 80% with symptoms))  recomincrease FEV <sub>1</sub> fr significant (post FEV <sub>1</sub> )  significant (post FEV <sub>1</sub> )  Woderate COPD (% predicted FEV <sub>1</sub> )  Severe COPD (% predicted FEV <sub>1</sub> )  Very severe (% predicted < 30%)	Spirometry results	1				7 _	NICI	
FEV1 (3390) (339S)  FVC (3396)  VC  ung function assessment indicates:  Normal lung function Restriction  Moderate COPD (% predicted FEV1 Severe COPD) (% predicted FEV1 Severe COPD)	FEV <sub>1</sub> (3390) (339S)  FVC (3396)  VC  ung function assessment indicates:  Normal lung function  Restriction  Mild COPD (% predicted FEV <sub>1</sub> $\geq$ 80% with symptoms))  FEV <sub>1</sub> frisignificant (post FEV <sub>1</sub> $\leq$ 100 friends (po	FEV <sub>1</sub> /FVC ratio	(339R)				7	recom	
FVC (3396)  VC (post FEV)  Lung function assessment indicates:  Normal lung function	FVC (3396)  VC (post FEV₁  ung function assessment indicates:  Normal lung function  Restriction   Moderate COPD (% predicted FEV₁ Severe COPD (% predicted	FEV <sub>1</sub>	(3390)	(339S)			<b></b>	FEV <sub>1</sub> fr	
.ung function assessment indicates:  Normal lung function Restriction  Moderate COPD (% predicted FEV <sub>1</sub> ) Severe COPD (% predicted FEV <sub>1</sub> )	ung function assessment indicates:  Normal lung function  Restriction  Mild COPD (% predicted FEV₁ ≥ 80% with symptoms))  □ Very severe (% predicted < 30%)	FVC	(3396)				S		
Normal lung function   Restriction   Moderate COPD (% predicted FE Severe COPD (% predicted FEV <sub>1</sub> )	Normal lung function $\Box$ Moderate COPD (% predicted FEV <sub>1</sub> Restriction $\Box$ Severe COPD (% predicted FEV <sub>1</sub> $\Box$ Mild COPD (% predicted FEV <sub>1</sub> $D$ Very severe (% predicted $D$ $D$ Very severe (% predicted $D$	VC					(p	ost FEV <sub>1</sub> -	
Normal lung function   Restriction   Moderate COPD (% predicted FE Severe COPD (% predicted FEV <sub>1</sub> )	Normal lung function $\Box$ Moderate COPD (% predicted FEV <sub>1</sub> Restriction $\Box$ Severe COPD (% predicted FEV <sub>1</sub> $\Box$ Mild COPD (% predicted FEV <sub>1</sub> $D$ Very severe (% predicted $D$ $D$ Very severe (% predicted $D$								
Restriction	Restriction $\Box$ Severe COPD (% predicted FEV <sub>1</sub> 4 Mild COPD (% predicted FEV <sub>1</sub> 2 80% with symptoms)) $\Box$ Very severe (% predicted < 30%)	Lung function asse	ssment indicate	s:					
	Mild COPD (% predicted FEV <sub>1</sub> ≥ 80% with symptoms)) □ Very severe (% predicted < 30%)	•	ion				` .	-	
n Mild COPD (% predicted FEV₁ ≥ 80% with symptoms)) □ Very severe (% predicted < 30%)							D (% predicte	d FEV <sub>1</sub>	
	ulse oximetry (%)								

#### References

- National Institute for Health and Clinical Excellence (NICE) Guideline for the Management of COPD. February 2004. Revised June 2010 Last accessed 28 June 2010:
  - http://guidance.nice.org.uk/CG101/NICEGuidance/doc/English
- Fletcher CM, Elmes PC, Fairbairn MB et al. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. BMJ 1959:2:257-266.
- Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001;56:880-7.
- Levy ML, Quanjer PH, Booker R, Cooper BG, Holmes S, Small I.
   Diagnostic Spirometry in Primary Care: Proposed standards for general
   practice compliant with American Thoracic Society and European
   Respiratory Society recommendations. A General Practice Airways Group
   (GPIAG) document, in association with the Association for Respiratory
   Technology & Physiology (ARTP) and Education for Health. Prim Care
   Resp J 2009;18(3):130-47. http://dx.doi.org/10.4104/pcrj.2009.00054
- COPD Assessment Tool (CATS) on line tool http://catestonline.co.uk/hcpgetting.htm
- National Institute for Health and Clinical Excellence (NICE) Guideline for the management of Depression in adults (CG90) October 2009. http://www.nice.org.uk/nicemedia/live/12329/45896/45896.pdf

# Further Information

- PCRS-UK Opinion Sheet 25. Reviewing People with COPD. June 2008.
   H Pinnock.
  - http://www.pcrs-uk.org/downloads/resources/os19\_copd\_review.pdf PCRS-UK Opinion Sheet 1. Spirometry. May 2010.
  - http://www.pcrs-uk.org/downloads/opinions/os1\_spirometry.pdf PCRS-UK Opinion Sheet 28. Pulse Oximetry.
  - http://www.pcrs-uk.org/downloads/resources/os28\_pulse\_oximetry.pdf
- PCRS-UK Protocol 1. Spirometry in COPD. S Reilly.
  http://www.pcrs-uk.org/downloads/resources/protocol01\_spirometry\_
  webfinal.doc
  - PCRS-UK Summary Guidance. Diagnosis and Management of COPD in Primary Care. Edition 3.
  - http://www.pcrs-uk.org/downloads/resources/copd\_guidelinebooklet\_final.pdf
  - Chronic Obstructive Pulmonary Disease NICE Guideline 101. http://guidance.nice.org.uk/CG101/NICEGuidance/doc/English Last accessed 28 June 2010
- An outcomes strategy for people with chronic obstructive pulmonary disease (COPD) and asthma in England https://www.gov.uk/government/uploads/system/uploads/attachment\_dat a/file/216139/dh\_128428.pdf

This protocol has been developed specifically to be utilised by primary care nurses delivering respiratory care. It has been produced as a general guide only. It must be stressed that the use of all, or part, of this protocol must be sanctioned and approved by the appropriate authorised individual from the practice or primary care organisation in which it is to be used. The PCRS-UK is neither responsible or liable, directly or indirectly for any form of damage or injury caused as a result of information provided in this document.

The PCRS-UK is not able to review or endorse any changes to this protocol.

Date of Preparation: October 2008 Revised: June 2010, March 2014

Author: Stephanie Austin, Vice Chair of Nurse Committee PCRS-UK and Head of Clinical Quality, NHS Derby City Conflict of interest: None Editor: Jane Scullion, PCRS-UK

Address: PCRS-UK, Unit 2, Warwick House, Kingsbury Road, Curdworth, Warwicks, B76 9EE Telephone: +44 (0)1675 477600 Facsimile: +44 (0)1361 331811 Websites: http://www.pcrs-uk.org, http://www.thepcrj.org Email: info@pcrs-uk.org

©PCRS-UK. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, without the prior permission of the PCRS-UK. The PCRS-UK is a registered charity (Charity Number: 1098117) and a company limited by guarantee (Company number 4298947).